CRY1
CRY1 (Cryptochrome 1) is a master regulator of the circadian clock, functioning as the primary "molecular brake" that ensures biological processes align with the 24-hour solar cycle. Along with its partner PER2, CRY1 enters the nucleus at night to physically block the CLOCK-BMAL1 complex, effectively resetting the cellular day. Beyond its role in sleep timing, CRY1 is a critical metabolic and genomic guardian; it represses hepatic gluconeogenesis to maintain stable blood sugar and protects the genome by coordinating DNA repair. The CRY1Δ11 mutation (rs1554338) is a major genetic cause of hereditary Delayed Sleep Phase Disorder (DSPD), creating the classic "night owl" phenotype by stretching the internal clock beyond 24 hours.
Key Takeaways
- •CRY1 is the essential "Night Watchman" that shuts down the positive arm of the circadian clock to allow for repair.
- •The CRY1Δ11 mutation is a primary genetic driver of "night owl" behavior (Delayed Sleep Phase Disorder).
- •CRY1 is a potent metabolic regulator; it directly represses gluconeogenesis and glucose oxidation.
- •Loss of CRY1 promotes tumor growth by increasing the stability of HIF-1α and disrupting the DNA damage response.
- •Maintaining robust CRY1 oscillations is fundamental to metabolic homeostasis and preventing premature cellular senescence.
Basic Information
- Gene Symbol
- CRY1
- Full Name
- Cryptochrome Circadian Regulator 1
- Also Known As
- PHLL1hCRY1
- Location
- 12q23.3
- Protein Type
- Transcriptional Repressor
- Protein Family
- Cryptochrome family
Related Isoforms
The canonical full-length protein active in the central and peripheral clocks.
Splice variant (missing exon 11) that over-binds CLOCK-BMAL1, causing sleep phase delay.
Key SNPs
The marker for the CRY1Δ11 mutation. Extends the circadian period, leading to Delayed Sleep Phase Disorder (DSPD).
Associated with major depressive disorder and altered mood regulation in GWAS cohorts.
Linked to cluster headaches and predicts the therapeutic response to lithium in bipolar patients.
Reported in studies investigating the risk of depressive relapse in patients with bipolar disorder.
Overview
CRY1 (Cryptochrome 1) is a master regulator of the circadian clock, functioning as the primary "molecular brake" that ensures biological processes align with the 24-hour solar cycle. Along with its partner PER2, CRY1 enters the nucleus at night to physically block the CLOCK-BMAL1 complex, effectively resetting the cellular day.
Beyond its role in sleep timing, CRY1 is a critical metabolic and genomic guardian; it represses hepatic gluconeogenesis to maintain stable blood sugar and protects the genome by coordinating DNA repair. The CRY1Δ11 mutation (rs1554338) is a major genetic cause of hereditary Delayed Sleep Phase Disorder (DSPD), creating the classic "night owl" phenotype by stretching the internal clock beyond 24 hours.
Upstream Regulators
CLOCK / BMAL1 Activator
The primary transcriptional activators that drive CRY1 expression during the positive limb of the clock.
Hippo Pathway (YAP/TAZ) Activator
YAP binds to the CRY1 promoter to increase its levels, linking cell growth and organ size to the clock.
Androgens (DHT) Activator
Dihydrotestosterone stimulates CRY1 expression, particularly in prostate tissue, influencing tissue-specific rhythms.
CK1δ / ε Modulator
Casein Kinases that phosphorylate CRY1 to regulate its stability, nuclear translocation, and degradation.
FBXL3 Inhibitor
E3 ubiquitin ligase that targets CRY1 for proteasomal degradation, resetting the clock for the next day.
AMPK Modulator
Energy sensor that phosphorylates CRY1, promoting its degradation to accelerate the clock in response to low energy.
Downstream Targets
CLOCK / BMAL1 Inhibits
Physically binds and inhibits the positive transcriptional complex, terminating the wake-phase program.
HIF-1α Inhibits
CRY1 is a negative regulator of the hypoxia response; its absence leads to over-stabilization of HIF-1α.
PDK1 Inhibits
Represses Pyruvate Dehydrogenase Kinase 1 to regulate the rate of glucose oxidation in the mitochondria.
Glucocorticoid Receptor Inhibits
Modulates stress hormone signaling, preventing the excessive metabolic response to cortisol.
p53 Modulates
Influences the timing of p53 degradation, linking the clock to the cell cycle and genomic maintenance.
G6PC Inhibits
Represses Glucose-6-Phosphatase, the rate-limiting step in hepatic glucose production.
Role in Aging
CRY1 is a central guardian against the "flattening" of physiological rhythms that characterizes aging. Its integrity ensures that the genome is protected and metabolism remains rhythmic across the lifespan.
Circadian Amplitude Decay
With age, the magnitude of CRY1 oscillations dampens, leading to fragmented sleep and the loss of distinct metabolic phases.
Genomic Guarding
CRY1 rhythmically coordinates DNA repair pathways (e.g., Homologous Recombination), protecting the genome from age-related mutations.
Senescence Prevention
By regulating the timing of p53 and cellular stress responses, CRY1 prevents premature entry into the permanent "growth arrest" of senescence.
Metabolic Resilience
Robust CRY1 rhythms are essential for maintaining hepatic insulin sensitivity and preventing the hyperglycemia associated with "metabolic aging."
Iron Homeostasis
CRY1 regulates ferritinophagy (iron-related cell death), ensuring that iron metabolism does not drive excessive oxidative damage over time.
Immune Regulation
Coordinates the timing of inflammatory cytokine production; its disruption contributes to the "inflammaging" phenotype.
Disorders & Diseases
Delayed Sleep Phase Disorder
The CRY1Δ11 mutation extends the circadian period beyond 24 hours, making early waking biologically difficult.
Type 2 Diabetes
Loss of CRY1-mediated repression of gluconeogenesis leads to elevated fasting blood sugar and insulin resistance.
Cancer
CRY1 deficiency stabilizes HIF-1α and disrupts DNA repair, promoting tumor growth and resistance to chemotherapy.
Major Depressive Disorder
Variants in CRY1 are associated with mood instability and seasonal variations in depression severity.
Metabolic Syndrome
Disruption of the CRY1-Glucocorticoid axis contributes to visceral obesity and systemic metabolic drift.
Deep Dive
The Molecular Brake: CRY1 and the Negative Limb
To understand CRY1, one must view the circadian clock as a self-resetting hourglass. While the “positive” arm (CLOCK-BMAL1) turns the hourglass over to start the day, CRY1 is the sand that eventually fills the bottom and stops the flow. Along with its partner PER2, CRY1 accumulates in the cytoplasm during the day. At night, it translocates into the nucleus to physically bind and inhibit the CLOCK-BMAL1 complex. This shutdown is essential for the cell to transition from “output mode” to “repair mode.”
The CRY1Δ11 Mutation: The Genetics of the “Night Owl”
The most significant human genetic finding in the circadian field is the CRY1Δ11 variant. This mutation causes the skipping of exon 11, resulting in a protein that lacks a specific regulatory tail.
- The Over-achieving Brake: The mutant CRY1 protein binds even more tightly to CLOCK-BMAL1 than the normal version.
- The Circadian Stretch: This makes the “night” phase of the clock last longer, stretching the internal day to roughly 24.5 or 25 hours.
- DSPD: Individuals with this mutation have Delayed Sleep Phase Disorder. Their bodies are biologically programmed to stay awake late into the night and struggle immensely with standard 9-to-5 schedules, representing a classic case of gene-environment misalignment.
Metabolic Gatekeeping: Beyond the Clock
CRY1 is a major player in hepatic glucose metabolism, acting independently of its role in the core clock to regulate blood sugar.
The Gluconeogenesis Brake: CRY1 directly interacts with the Glucocorticoid Receptor (GR) and the G-protein Gsα to inhibit the production of glucose in the liver. It ensures that the liver doesn’t over-produce sugar during the night.
Diabetes Link: Disruption of this CRY1-mediated brake is a primary driver of high fasting blood sugar. Research has shown that activating CRY1 or stabilizing its rhythm can improve insulin sensitivity and glucose tolerance, making it a “metabolic anchor” for systemic health.
Genomic Stability and the Hypoxia Response
CRY1 serves as a critical link between the biological clock and the cell’s defense against cancer.
DNA Repair Coordination: CRY1 regulates the timing of several DNA repair pathways. By ensuring that repair enzymes are most active when the genome is most vulnerable (during peak metabolism), CRY1 prevents the accumulation of mutations that lead to aging and cancer.
HIF-1α Regulation: CRY1 is a negative regulator of HIF-1α, the master sensor of low oxygen. In cells lacking CRY1, HIF-1α becomes over-stabilized, even in normal oxygen conditions. This “pseudohypoxia” triggers the formation of new blood vessels and metabolic shifts that are exploited by tumors to grow and survive, highlighting CRY1 as a foundational tumor suppressor gene.